Denali Therapeutics Inc DNLI

NAS: DNLI | ISIN: US24823R1059   30/04/2025
16,65 USD (+0,91%)
(+0,91%)   30/04/2025

1 november 2023 · Flagship Pioneering Launches Pioneering Intelligence · Persbericht

11 september 2023 · Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer · Persbericht

29 augustus 2023 · Invaio achieves first registration for citrus greening solution featuring Trecise™ technology · Persbericht

21 juni 2023 · Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs · Persbericht

16 mei 2023 · Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry · Persbericht

28 februari 2022 · Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs · Persbericht

15 februari 2022 · Invaio Sciences Strengthens Its Board Of Directors With The Appointment Of Hugh Grant · Persbericht

13 oktober 2021 · Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change · Persbericht

15 juni 2021 · Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative · Persbericht

25 mei 2021 · Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture · Persbericht

19 mei 2021 · Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening · Persbericht

30 maart 2021 · Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer · Persbericht

25 februari 2021 · Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights · Persbericht

25 februari 2021 · Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target · Persbericht

12 februari 2021 · Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II) · Persbericht

5 februari 2021 · Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™ · Persbericht

11 januari 2021 · Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors · Persbericht

8 januari 2021 · Denali Therapeutics Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Broad Therapeutic Portfolio in Neurodegeneration · Persbericht

Mijn selecties